On June 27, 2023, the Food and Drug Administration’s ("FDA") Office of Prescription Drug Promotion ("OPDP") published a final guidance (the "Final Guidance") on Presenting Quantitative.
As the life sciences industry continues to expand and grow increasingly complex, so does its legal, regulatory, and compliance landscape. To help companies and investors navigate the.
The wait is finally over. On June 7, 2023, after remaining silent for over an entire year, the US Food and Drug Administration ("FDA") Office of Prescription Drug Promotion ("OPDP") issued its first untitled.
The wait is finally over. On June 7, 2023, after remaining silent for over an entire year, the US Food and Drug Administration (“FDA”) Office of Prescription Drug Promotion (“OPDP”).
US FDA OPDP issued first untitled letter of 2023 to Xeris Pharmaceuticals concerning promotional material for Recorlev tablets, citing misleading claims on company webpages.